Half-sandwich arene ruthenium(II) and osmium(II) thiosemicarbazone complexes : solution behavior and antiproliferative activity

We report the synthesis, characterization and antiproliferative activity of organo-osmium(II) and organo-ruthenium(II) half-sandwich complexes [(η6-p-cym)Os(L)Cl]Cl (1 and 2) and [(η6-p-cym)Ru(L)Cl]Cl (3 and 4), where L = N-(2-hydroxy)-3-metoxybenzylidenethiosemicarbazide (L1) or N-(2,3-dihydroxybenzylidene)-3-phenylthiosemicarbazide (L2), respectively. X-ray crystallography showed that all four complexes possess half-sandwich pseudo-octahedral “three- leg piano-stool” structures, with a neutral N,S-chelating thiosemicarbazone ligand and a terminal chloride occupying three coordinative positions. In methanol, E/Z isomerization of the coordinated thiosemicarbazone ligand was observed, while in an aprotic solvent like acetone, partial dissociation of the ligand occurs, reaching complete displacement in a more coordinating solvent like DMSO. In general, the complexes exhibited good activity towards A2780 ovarian, A2780Cis cisplatin-resistant ovarian, A549 lung, HCT116 colon, and PC3 prostate cancer cells. In particular ruthenium complex 3 does not present cross-resistance with the clinical drug cisplatin in the A2780 human ovarian cancer cell line. The complexes were more active than the free thiosemicarbazone ligands, especially in A549 and HCT116 cells with po- tency improvements of up to 20-fold between the organic ligand L1 and the ruthenium complex 1

Half-Sandwich Arene Ruthenium(II) and Osmium(II) Thiosemicarbazone Complexes: Solution Behavior and Antiproliferative Activity

We report the synthesis, characterization, and antiproliferative activity of organo-osmium­(II) and organo-ruthenium­(II) half-sandwich complexes [(η⁶-<i>p</i>-cym)­Os­(L)­Cl]­Cl (<b>1</b> and <b>2</b>) and [(η⁶-<i>p</i>-cym)­Ru­(L)­Cl]Cl (<b>3</b> and <b>4</b>), where L = <i>N</i>-(2-hydroxy)-3-methoxybenzylidenethiosemicarbazide (<b>L1</b>) or <i>N</i>-(2,3-dihydroxybenzylidene)-3-phenylthiosemicarbazide (<b>L2</b>), respectively. X-ray crystallography showed that all four complexes possess half-sandwich pseudo-octahedral “three-legged piano-stool” structures, with a neutral N,S-chelating thiosemicarbazone ligand and a terminal chloride occupying three coordination positions. In methanol, <i>E</i>/<i>Z</i> isomerization of the coordinated thiosemicarbazone ligand was observed, while in an aprotic solvent like acetone, partial dissociation of the ligand occurs, reaching complete displacement in a more coordinating solvent like DMSO. In general, the complexes exhibited good activity toward A2780 ovarian, A2780Cis cisplatin-resistant ovarian, A549 lung, HCT116 colon, and PC3 prostate cancer cells. In particular, ruthenium complex <b>3</b> does not present cross-resistance with the clinical drug cisplatin in the A2780 human ovarian cancer cell line. The complexes were more active than the free thiosemicarbazone ligands, especially in A549 and HCT116 cells with potency improvements of up to 20-fold between organic ligand <b>L1</b> and ruthenium complex <b>1</b>